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Antimicrobial peptides are constituents of the first-
line innate mucosal defense system that acts as
a barrier to establishment of infection. The highly
successful human gastric pathogen, Helicobacter
pylori, is able to persistently colonize its host
despite inducing expression of several antimicrobial
peptides, including human b-defensin 3 (hBD3). We
find that hBD3 is highly active against H. pylori
in vitro and is rapidly induced during early infection
via EGFR-dependent activation of MAP kinase and
JAK/STAT signaling. However, during prolonged
infection, hBD3 was subsequently downregulated
by the H. pylori virulence determinant CagA. Upon
translocation into host cells, CagA activated the
cellular tyrosine phosphatase, SHP-2, terminating
EGFR activation and downstream signaling and
increasing bacterial viability. Chemical inhibition
and knockdown of SHP-2 expression rescued
hBD3 synthesis and bactericidal activity. Thus, we
reveal how cagPAI-positive H. pylori strains use
CagA to evade a key innate mucosal defense
pathway to support the establishment of persistent
infection.
INTRODUCTION
The human gastric pathogen Helicobacter pylori has evolved
effective means to evade host immune responses, enabling it
to survive within the harsh environment of the gastric mucosa
and, thus far, resist effective vaccination strategies (Aebischer
et al., 2008). Examples of survival tactics used by H. pylori
include subversion of acquired immunity via suppression of
T cell activation (Gebert et al., 2003), the expression of low endo-
toxic lipopolysacharide (Muotiala et al., 1992), and strong flagella
mediatedmotility (Eaton et al., 1996; Haas et al., 1993)—a feature
supported by its spiral morphology (Sycuro et al., 2010). Infec-
tion with H. pylori can induce severe human gastric disease
such as peptic ulcer, adenocarcinoma, and MALT lymphoma,
and persistent colonization by this pathogen is considered
prerequisite for serious pathology.576 Cell Host & Microbe 11, 576–586, June 14, 2012 ª2012 ElsevierH. pylori strains expressing a functional type IV secretion
system (T4SS) translocate the bacterial effector protein, CagA,
into host epithelial cells (Asahi et al., 2000; Backert et al., 2000;
Higashi et al., 2002b; Odenbreit et al., 2000; Stein et al., 2000),
where it contributes to infection pathology (Hatakeyama,
2008). Once inside host cells, CagA is phosphorylated and
targets multiple enzymes, such as the oncogenic tyrosine phos-
phatase, SHP-2, and the receptor tyrosine kinase epidermal
growth factor receptor (EGFR), to manipulate host cell signaling
(Bauer et al., 2009; Higashi et al., 2002b). SHP-2 and EGFR are
important for host cell function and are also implicated in carci-
nogenesis since they regulate fundamental cellular responses
such as proliferation, growth, and apoptosis (Yarden, 2001).
Whereas SHP-2 is strongly activated during H. pylori infection
in a CagA-dependent manner (Higashi et al., 2002b), ligand-
mediated endocytosis of the EGFR is disrupted by CagA (Bauer
et al., 2009). Interestingly, SHP-2 and the EGFR are also func-
tionally associated since SHP-2 dephosphorylates the EGFR
and downstream signaling pathway intermediates to initiate
negative- (Zhang et al., 2002) and positive- (Agazie and Hayman,
2003; Cunnick et al., 2000) feedback loops (Kapoor et al., 2004).
The host has numerous counterattack mechanisms aimed at
impeding mucosal infections. Previous studies have reported
the strong induction of several potent antimicrobial cationic
defensin peptides during the early stages of infectionwith various
bacterial species (Lee and Josenhans, 2005; Menendez and Fin-
lay, 2007; Vaishnava et al., 2011). These short peptides are
constitutively expressedor induced, and theycontribute to innate
and adaptive immunity through effector and regulatory functions
(Dhople et al., 2006). Since defensins are effective against Gram-
negativeand -positivebacteria, fungi, parasites, andviruses, they
are important components of first-line host defenses (Lehrer
et al., 1993). They exert their antimicrobial impact via charge-
mediated binding to membranes to form pores, ion channels, or
extensive membrane rupture, resulting in bacterial lysis (Selsted
andOuellette, 2005;Wiesner and Vilcinskas, 2010). Interestingly,
defensins are also reported to function in host processes such as
wound closure (Hirsch et al., 2009), mitogenesis, and neovascu-
larization (Selsted and Ouellette, 2005). The human b-defensin
(hBD3) exhibits broad and potent salt-insensitive antimicrobial
activity (Boniotto et al., 2003; Harder et al., 2001), while the
activity of the human b-defensin 2 (hBD2) is highly salt sensitive
(Bals et al., 1998; Singh et al., 1998).
Recent work has shown that H. pylori infection induces the
expression of several human b-defensins. Besides hBD2, whichInc.
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man et al., 2010; Wada et al., 2001), hBD3 and hBD4 (Boughan
et al., 2006; Otte et al., 2009) were found to be upregulated
in vitro and in vivo, respectively. However, details of the molec-
ular mechanisms of microbe-induced defensin expression are
fragmentary, and possible strategies employed by H. pylori to
circumvent the antimicrobial action of b-defensins are unknown.
Here we show that H. pylori is highly susceptible to hBD3 and
that infection induced early hBD3 synthesis in human gastric
epithelial cells in an EGFR dependent manner. However, after
initial hBD3 synthesis, we observed CagA-dependent suppres-
sion of hBD3 synthesis, which resulted from SHP-2 activation
and subsequent EGFR dephosphorylation and facilitated bacte-
rial survival. Our data not only provide a functional explanation
for the prominent CagA-SHP-2 interaction (Higashi et al.,
2002b), but also demonstrate a key function of CagA for the
suppression of innate immunity.
RESULTS
hBD3 Exerts Strong, Strain-Independent Antimicrobial
Activity against H. pylori
Since hBD3 has known antimicrobial activity against a variety of
bacterial pathogens (Menendez and Finlay, 2007), we examined
the ability of H. pylori strains P1, P12, and G27 to induce hBD3
expression in human gastric epithelial cells. hBD3 was detect-
able at 4 hr postinfection (p.i.) in AGS, MKN-28, and MKN-74
cells, and levels increased at 24 hr p.i (Figure 1A and Figure S1A
available online), thus indicating that hBD3 induction is an innate
response common to H. pylori infected human epithelial cells.
hBD3 induction was not unique to H. pylori; the Gram-negative
bacteria Salmonella typhimurium and enteropathogenic Escher-
ichia coli also induced its synthesis, although the Gram-positive
bacterium Propionibacterium acnes did not (Figure S1B). Neither
heat-inactivated bacteria nor treatment with bacterial superna-
tant induced hBD3 (Figure 1B), thus suggesting that a labile
and/or bacterially translocated factor was responsible for induc-
tion of hBD3. H. pylori induced hBD3 expression was TFSS and
CagA independent as the isogenic mutant P1DcagA and the
TFSS defective mutant P1DvirB11 (abrogated CagA transloca-
tion) induced hBD3 comparably to the P1 strain at 24 hr p.i.
(Figure S1C).
The relative bactericidal impact of hBD3 and hBD2 against
H. pylori has been debated in the literature (George et al.,
2003; Grubman et al., 2010). Here, in a host cell-free assay,
hBD3 exhibited strong, broad-spectrum bactericidal activity:
a concentration of 10 mM reduced bacterial survival of all strains
tested by 100% (Figures 1C and S1D–S1F). hBD2 was less
active against H. pylori and its activity was strain dependent
and highly salt sensitive (Figures 1C and S1D–S1F) with maximal
80% reduction of bacterial survival in nonphysiological 50 mM
NaCl (10 mM hBD2).
Colocalization of hBD3 with less viable coccoid forms of
H. pylori (Andersen and Rasmussen, 2009) was observed by
immunofluorescence microscopy upon infection of cultured
human tissue (Figure 1D), and in a cell culture model, bacterial
viability increased 2-fold in hBD3 short hairpin RNA (shRNA)
stable knockdown cells (Figures 1E and 1F). Together, these
data clearly show that hBD3 is rapidly induced in humanCell Hepithelial cells in response to H. pylori infection, which leads to
a significant reduction of pathogen viability.
H. pylori Inhibits Expression of Antimicrobial hBD3
in Gastric Epithelial Cells during Prolonged Infection
Synthesis of hBD3 ceased at the messenger RNA (mRNA) level
(Figure 2A) by 24 hr p.i. and at the protein level 24–48 hr p.i. (Fig-
ure 2B). By contrast, hBD2 protein levels did not change during
prolonged infection (up to 48 hr p.i.) (Figure S2A). Immunofluo-
rescence microscopy of infected cells confirmed the transient
production of hBD3 (Figure 2C). At 24 hr p.i., hBD3 colocalized
with adherent bacteria, most of which were of coccoid form (Fig-
ure 2D). Strikingly, 48 hr p.i., both hBD3 and coccoid forms were
no longer detectable. Quantification of immunofluorescence
demonstrated significantly increased (2.5-fold) hBD3 signal in
cells 24 hr p.i. compared with 48 hr p.i. and noninfected cells
(Figure 2E). Cell viability during the infection period was not
compromised (multiplicity of infection [MOI] 20; Figures S2B–
S2D). Taken together, these data suggest that H. pylori downre-
gulates hBD3 later in infection to escape its microbicidal impact.
Initial hBD3 Expression Is Triggered by EGFR-Mediated
Activation of MAP and JAK Kinases
The EGFR pathway is activated by H. pylori early in infection
(Keates et al., 2001; Wallasch et al., 2002) and is thought to be
involved in H. pylori-induced hBD3 expression (Boughan et al.,
2006). We used the EGFR-specific inhibitors, AG1478 and Gefi-
tinib, duringH. pylori infection of AGS cells to determine whether
EGFR signaling is involved in hBD3 expression. EGFR inhibition
largely abolished hBD3 protein and mRNA expression (Figures
3A and 3B). Likewise, inhibition of the MAP kinase, MEK1/2
(UO126), or Janus kinase 2 (AG490) reduced hBD3 expression
levels in infected cells and the application of both inhibitors
together almost totally abolished hBD3 expression (Figure 3C).
These data show that EGFR/MEK and EGFR/JAK/STAT
signaling is required for hBD3 upregulation by H. pylori.
Since initial hBD3 upregulation was found to be EGFR depen-
dent, we monitored EGFR transactivation by immunoblot in
noninfected and P1 infected AGS cells after treatment with the
EGFR ligand, EGF. We detected EGFR phosphorylation in both
non-infected cells and cells infected for% 8 hr. No EGFR phos-
phorylation was detected after prolonged infection of AGS cells
(20 hr; Figures 3D and S3A), MKN-28 or MKN-74 cells (24 hr; Fig-
ure S3B). Inhibition of EGFR phosphorylation was MOI depen-
dent (Figure S3C), thus providing evidence for a direct bacterial
effect in EGFR inhibition.
During transactivation the EGFR is phosphorylated at multiple
tyrosine residues (Hubbard and Miller, 2007). We analyzed the
phosphorylation status of EGFR Y845, Y1045, Y992, and
Y1068 residues during prolonged infection. Phosphorylation of
all four tyrosine residues was reduced, which could not be attrib-
uted to decreased EGFR protein levels (Figures 3E and S3D).
Consistent with this observation, we previously found the
EGFR Y1173 residue to be phosphorylated at 24 hr p.i.; phos-
phorylation of this particular residue inactivated endocytosis
and subsequent signaling (Bauer et al., 2009). EGFR down-
stream signaling, determined by EGF-dependent formation of
a phosphorylated EGFR/Grb2/SHC protein complex, was
inhibited after 24 hr p.i. (Figure S3E). Heparin binding-EGFost & Microbe 11, 576–586, June 14, 2012 ª2012 Elsevier Inc. 577
Figure 1. H. pylori-Induced hBD3 Exerts Strong Antimicrobial Activity
(A) AGS cells were infected with H. pylori wild-type strains P1, P12, and G27 (all MOI 100) for the indicated time points. Infected and noninfected (NI) cells were
lysed and analyzed for hBD3 expression by immunoblot. Actin serves as a loading control.
(B) P1 was heat inactivated via incubation at indicated temperatures for 45 min. AGS cells were infected with untreated (P1), bacterial supernatant (SN), and heat
inactivated bacteria for 8 hr (MOI 100). Bacterial incubation medium (BHI) was used as control. Cells were lysed and analyzed for hBD3 expression by immu-
noblot. Actin serves as a loading control.
(C) Antimicrobial activity assay of hBD3- and hBD2-treated P1. Bacteria (1 3 105) were incubated for 2 hr with the indicated peptide concentrations in the
indicated NaCl concentrations (PBS). Colony forming units/ml (CFU/ml) were quantified 3 days later. Data are expressed as percentage bacterial survival relative
to the untreated control (UT).
(D) Confocal immunofluorescence staining of P1 infected tissue culture (Fallopian tubes). hBD3 expression was detected with an anti hBD3 antibody (green).
H. pylori was visualized with an anti-urease B antibody (red). Nuclei were stained with DraQ5 (blue). The scale bar represents 50 mm.
(E) Stable hBD3 knockdown cells (AGS_hBD3_KD_1 and AGS_hBD3_KD_2) were infected with P1 (MOI 100). 24 hr p.i., a CFU assay was performed to quantify
the bacterial survival rate. AGS cells expressing shRNA against luciferase (AGS_Luci) were used as control.
(F) RT-PCR analysis of hBD3 mRNA expression in P1 infected (MOI 100; 4 hr p.i.) stable shRNA-mediated hBD3 knockdown cells (AGS_hBD3 KD_1 and
AGS_hBD3 KD_2). AGS_Luci cells serve as control.
Blots in (A) and (B) and images in (C), (E), and (F) are representative of three independent experiments. Data in (C), (E), and (F) showmean ± SD of three technical
replicates. Statistical significance in (E) was calculated with t test analysis (** indicates p value < 0.009). See also Figure S1.
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a ligand-independent but EGFR-dependent effect. Moreover,
the observed inhibition of signal transduction was not a general
consequence of prolonged infection, as transactivation of c-Met,
an EGFR-related receptor tyrosine kinase previously implicated
in H. pylori infection (Churin et al., 2003), was not reduced (Fig-
ure S3G). These findings provide strong evidence for selective
EGFR inhibition during prolonged infection.578 Cell Host & Microbe 11, 576–586, June 14, 2012 ª2012 ElsevierInhibition of hBD3 Expression by H. pylori
CagA-Dependent EGFR Inactivation
The H. pylori effector protein, CagA, interferes with host cell
signal transduction pathways (Backert and Selbach, 2008;
Costa et al., 2009). To investigate its potential role in hBD3
and EGFR inactivation, we infected AGS cells with strains
P1DcagA and P1DvirB11. hBD3 was not downregulated in
AGS cells infected with either strain (Figures 4A, S4A, andInc.
Figure 2. H. pylori Inhibits Expression of hBD3 in Gastric Epithelial Cells during Prolonged Infection
(A) RT-PCR analysis of hBD3 mRNA expression in infected cells (P1, MOI 100). Expression is relative to noninfected control (NI). Data show mean ± SD of three
independent experiments. h p.i., hours postinfection.
(B) Immunoblot of hBD3 expression at 2, 24, 48, and 72 hr p.i. (P1; MOI 20, 100). Actin serves as a loading control. The blot is representative of three independent
experiments.
(C) Confocal images of hBD3 expression in P1-infected AGS cells (24 and 48 hr; MOI 20) and noninfected cells (NI). hBD3was stained with an anti-hBD3 antibody
(red), and bacteria are visualized with an anti-CagA antibody (green). Nuclei are stained with DraQ5 (blue). Scale bars represent 10 mm. Images are representative
of three independent experiments.
(D) 3D reconstruction of one representative confocal image of 24 hr infected cells (red, hBD3; green, bacteria; blue, DNA).
(E) Quantification of mean hBD3 signal intensity of at least three independent experiments of noninfected (NI), 24 hr infected, and 48 hr infected cells, shown as
mean ± SD. Statistical significance was calculated using t test analysis (* indicates p value < 0.05).
See also Figure S2.
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Figure 3. EGFR Regulation of hBD3 Expres-
sion Is Dependent on Duration of Infection
AGS cells were infected with P1 (MOI 100).
(A–C) Before and during infection cells were
treated with inhibitors against EGFR (A and B) or
MAP (UO126; 20 mM) or Janus (AG490; 20 mM)
kinases (C).
(A) Immunoblot analysis of hBD3 expression of
infected and noninfected (NI) cells 24 hr p.i.
treated with indicated concentration of AG1478.
Actin serves as a loading control.
(B) RT-PCR analysis of hBD3 mRNA expression in
P1-infected and noninfected (NI) cells after 8 hr of
infection (AG1478, Gefitinib; 10 mM). DMSO serves
as a control.
(C) Immunoblot analysis of hBD3 expression of
infected and noninfected (NI) cells 2 and 4 hr p.i.
treated with UO126 or AG490. Actin serves as
a loading control.
(D) EGFR phosphorylation was analyzed after
different time points of infection by immunoblot-
ting with an anti-phosphotyrosine antibody after
treatment of infected cells with 100 ng/ml EGF for
5 min. Phosphorylation intensities were quantified
(pYEGFR) and expressed as a percentage relative
to noninfected (NI) stimulated cells.
(E) Immunoblot analysis of EGFR phosphorylation
at specific tyrosines in infected (P1) and nonin-
fected (NI) cells (24 hr p.i.). Antibodies against
pY845, pY1045, pY992, and pY1068 were used.
EGFR serves as a loading control.
Blots in (A), (C), and (E) are representative of three
independent experiments. Data in (B) and (D) are
mean ± SD of three independent experiments. See
also Figure S3.
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synthesis. Moreover, neither strain inhibited EGFR phosphoryla-
tion in EGF-treated cells, showing that CagA is essential for
EGFR inactivation (Figure 4B). These data were supported by
the observation that infection of mouse lung epithelial cells
(MLE-12) or mouse fibroblasts (SYF) resulted in neither CagA
phosphorylation nor EGFR inhibition 24 hr after infection with
P1 (Figure S4C). Transient expression of constitutively active
EGFR (EGFR L858R) (Uchida et al., 2007) restored hBD3
mRNA expression 24 hr p.i., as did overexpression of WT
EGFR (Figure 4C). It is of note that cells expressing EGFR
L858R produced higher hBD3 mRNA levels even in the absence
of infection, thus confirming the EGFR-dependent induction of
hBD3 (Figure 4C). This finding is consistent with our previous
observation that infection with H. pylori leads to enhanced
surface exposition of EGFR in the late phase (Bauer et al.,
2009), thereby enabling increased signaling of hyper-exposed
EGFR L858R.
Cells infected with an isogenic mutant strain expressing non-
phosphorylatable CagA (G27cagAEPISA) showed restored
EGFR transactivation 24 hr p.i., unlike strains P1 and G27 or
the recomplemented mutant P1DcagA/cagA (Figure 4D). Since
CagA inactivates Src (Selbach et al., 2003), a nonreceptor580 Cell Host & Microbe 11, 576–586, June 14, 2012 ª2012 Elseviertyrosine kinase that phosphorylates the EGFR (Lombardo
et al., 1995), we transiently overexpressed constitutively active
Src in AGS cells to investigate whether CagAmediated inhibition
of Src was responsible for the CagA-dependent block of EGFR
phosphorylation. Although, the overall tyrosine phosphorylation
level increased, EGFR transactivation was not restored in
infected cells (Figure S4D). Thus, hBD3 expression is blocked
during prolonged infections with H. pylori via a selective inhibi-
tion of EGFR, which is dependent on CagA translocation and
phosphorylation but independent of CagA mediated Src
inactivation.
SHP-2 Mediates CagA-Dependent EGFR and hBD3
Inhibition and Increases Bacterial Viability
Phosphorylated CagA activates the tyrosine phosphatase,
SHP-2 (Higashi et al., 2002b), which in turn regulates EGFR
signaling by direct EGFR dephosphorylation or dephosphoryla-
tion of downstream factors such as GTPase-activating proteins
(Neel et al., 2003). Here, both small interfering RNA (siRNA)
depletion and chemical inhibition (orthovanadate) of SHP-2
rescued EGFR transactivation in infected cells (Figures 5A
and S5A) and demonstrated a role for SHP-2 in inhibition of
EGFR transactivation during infection. Notably, consistentInc.
Figure 4. CagA-Dependent Selective Inhibi-
tion of EGFR Inhibits hBD3 Synthesis
AGS cells were infected with either P1 or the
isogenic deletion mutants P1DcagA and
P1DvirB11 (MOI 100; 24 hr) and subsequently
treated with 100 ng/ml EGF for 5 min.
(A) RT-PCR analysis of hBD3 mRNA expression
infected with P1DcagA. Data are expressed as
a percentage relative to noninfected (NI) cells.
(B) Immunoblot analysis of EGFR and CagA
phosphorylation with an anti-phosphotyrosine
antibody. Actin serves as a loading control.
(C) AGS cells were transfected with EGFR
constructs encoding either constitutively active
EGFR (EGFR L858R) or wild-type EGFR
(EGFR WT). Twenty-four hours after transfection,
cells were infected with P1. Cellular RNA
was extracted and hBD3 mRNA measured by
RT-PCR 24 hr p.i.
(D) Immunoblot analysis of EGFR and CagA
phosphorylation with an anti-phosphotyrosine
antibody. Actin serves as a loading control. AGS
cells were infected with the wild-type strains P1
or G27 and with P1DcagA, the recomplemented
mutant P1DcagA/cagA, or the nonphosphory-
latable CagA mutant G27cagAEPISA.
Data in (A) and (C) aremean ± SD of three technical
replicates. Bar graphs in (A) and (C) and blots in (B)
and (D) are representative of three independent
experiments. See also Figure S4.
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SHP-2 (Higashi et al., 2002b), increased concentrations of
orthovanadate were needed to elevate tyrosine phosphoryla-
tion levels in infected cells (Figure S5A). This notion of elevated
SHP-2 activity in infected cells was corroborated by increased
SHP-2 phosphorylation levels in H. pylori-infected cells
(Figure S5B).
Since EGFR transactivation was restored under SHP-2
knockdown conditions (Figure 5A), we also anticipated resto-
ration of H. pylori dependent hBD3 expression. An infected
stable SHP-2 shRNA knockdown cell line (SHP2-4KD)
displayed rescued hBD3 synthesis 24 hr p.i. (Figures 5B and
S5C). siRNA knockdown of SHP-2 confirmed these results
although knockdown efficiency was less pronounced then in
SHP2-4KD cells (Figures S5D and S5E). hBD3 expression
was not decreased in SHP2 deficient cells 48 hr p.i. (Fig-
ure 5C), and hBD3 signal intensity was 6-fold stronger
compared with WT cells (Figure 5D). Moreover, in contrast
to WT cells, hBD3 and H. pylori colocalized in SHP-2 knock-
down cells 48 hr p.i. (Figure 5C). The high level of hBD3 in
stable SHP-2 knockdown cells correlated with reduced bacte-
rial survival after only 24 hr of infection (Figure 5E), and viability
of both attached (PE) and free swimming (SN) bacteria was
significantly reduced upon SHP-2 knockdown (Figure 5F).
Despite incomplete hBD3 knockdown, siRNA knockdown ofCell Host & Microbe 11, 576–5hBD3 in SHP2-4KD cells (sihBD3)
partially rescued bacterial viability—9-
fold increased viability compared with
control (Figures 5G and S5F). These
findings provide evidence for SHP-2-and CagA-dependent inhibition of EGFR transactivation, which
culminates in the inhibition of hBD3 expression and thus
increased H. pylori viability.
DISCUSSION
H. pylori has evolved effective means to combat host immunity
and to persistently colonize the human gastric niche (Aebischer
et al., 2010). Here, we demonstrate a central function for CagA,
a major bacterial virulence factor that is translocated into host
cells (Asahi et al., 2000; Backert et al., 2000; Higashi et al.,
2002b; Odenbreit et al., 2000; Stein et al., 2000). CagA sup-
pressed a first-line innate defense mechanism by selectively
inhibiting the synthesis of hBD3, a defensin and key mediator
of innate immunity that we found to be particularly active against
H. pylori. We observed that synthesis of hBD3 was initially
induced after H. pylori infection via EGFR transactivation and
downstream signaling. However, subsequent EGFR dephos-
phorylation abrogated hBD3 synthesis and increased bacterial
viability. EGFR dephosphorylation was mediated by SHP-2,
which was activated by phosphorylated CagA (Higashi et al.,
2002b). Our observations highlight an interesting function for
CagA—namely, the manipulation of a host innate immune
response, which could contribute to persistent gastric coloniza-
tion by H. pylori (see the Graphical Abstract).86, June 14, 2012 ª2012 Elsevier Inc. 581
Figure 5. Inhibition of EGFR and hBD3 Expression via SHP-2 Enables Bacterial Survival
(A) AGS cells were transfected with siRNAs targeting SHP-2 (siRNA SHP-2) or luciferase control (siRNA Luci). Three days after transfection, cells were infected
with P1 (MOI 100) and analyzed 24 hr later. For EGFR phosphorylation analysis, infected and noninfected (NI) cells were stimulatedwith EGF (100 ng/ml) for 5min.
EGFR phosphorylation (EGFR pY) was analyzed by immunoblotting with an anti-phosphotyrosine antibody. Actin serves as a loading control. Graph depicts
phosphorylation intensities (pEGFR) as a percentage relative to noninfected unstimulated cells.
(B) A stable SHP-2 knockdown cell line was generated via genomic lentiviral shRNA integration (SHP2-4KD). The graph shows hBD3mRNA expression in infected
and noninfected (NI) AGS and SHP2-4KD cells as measured by RT-PCR.
(C) Confocal immunofluorescence analysis of infected AGS and SHP2-4KD cells (MOI 20). Cells were stained with an anti-hBD3 antibody (red) or anti-CagA
antibody (blue) to visualizeH. pylori. Knockdown cells express GFP (green) as a reporter construct for efficient lentiviral integration. Two representative figures for
each sample are shown. The scale bar represents 10 mm.
(D) Quantification of hBD3 signal intensity in AGS WT and SHP-2-deficient cells 48 hr p.i. in relation to AGS WT cells (100%).
(E) Quantification of bacterial signal intensity of SHP2-4KD cells 24 hr p.i. (MOI 20) in relation to AGS WT cells.
(F and G) Bacterial viability was monitored by counting CFUs of infected cells 24 hr p.i.
(F) Numbers of free swimming (supernatant; SN) and attached (pellet; PE) bacteria, expressed as colony-forming units/ml (CFU/ml), in AGS and
SHP2-4KD cells.
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H. pylori Evades hBD3 Bactericidal ActivityAccording to our in vitro data, hBD3 acts as a broadly active
and highly potent antimicrobial agent against H. pylori; more-
over, we found hBD3 to be more effective than hBD2. This
corroborates previous findings (George et al., 2003; Kawauchi
et al., 2006), but contrasts with a report that failed to detect
significant activity of hBD3 against H. pylori (Grubman et al.,
2010). We included the strain used in that report in our analyses
(H. pylori 251) and found it to be hBD3 sensitive. Consistent with
published findings (George et al., 2003), we also observed
limited, salt-sensitive antimicrobial activity for hBD2 against
the fourH. pylori strains tested in vitro. However, hBD2was inac-
tive against all strains in isotonic solution and had inconsistent or
limited antimicrobial activity in hypotonic solutions (50–80 mM),
thus questioning significant activity of hBD2 against H. pylori
in vivo at gastric mucosal sites. Considerable phenotypic diver-
sity exists in the LPS O-antigen chain between individual cells of
bacterial communities (Nilsson et al., 2008), which could further
contribute to variations in the susceptibility of H. pylori to defen-
sins (Cullen et al., 2011).
We observed selective downregulation of hBD3 in epithelial
cells from 24 hr p.i. (on the mRNA level as early as 10 hr p.i. Fig-
ure S4B). This contrasted with hBD2 levels, which remained
elevated 48 hr p.i. Although it is difficult to extrapolate from the
time course of in vitro infections to in vivo steady state condi-
tions, hBD3 was not upregulated in gastric biopsies from
patients with persistent complaints in three separate studies
(Hofman et al., 2007; Mannick et al., 2004; Vordenba¨umen
et al., 2010) and was upregulated in only one study of gastritis
patients, in which the CagA status of infecting strains was not
reported (Kawauchi et al., 2006). By contrast, hBD2 has been
found to be upregulated in H. pylori-infected patients (Mannick
et al., 2004; Vordenba¨umen et al., 2010). Overall, this is sugges-
tive of a scenario in which H. pylori selectively inhibits a bacteri-
cidal host response. In so doing, H. pylori might restrict the
growth and colonization of hBD2-sensitive, potentially
competing microbes, which could possibly also affect gastroin-
testinal microbiota (Aebischer et al., 2006; Gill and Finlay, 2011).
Interestingly, other pathogens (including Neisseria, Shigella, and
Candida) also downregulate antimicrobial peptides by as yet
undetermined mechanisms (Bergman et al., 2005; Islam et al.,
2001; Sperandio et al., 2008).
H. pylori is an ancient pathogen that has coevolved with its
human hosts over tens of thousands of years (Falush et al.,
2003). Host factors, the expression of which may vary between
host populations, have likely contributed to the accumulation
of virulence factors by this pathogen. Notably, East Asian strains
possess variant forms of CagA that more aggressively interfere
with host cell signaling as compared to strains common in
western populations (Higashi et al., 2002a), whereas South
African strains (hpAfrica2) are devoid of the functional type IV
secretion system, including CagA (Olbermann et al., 2010).
This raises the question of how different H. pylori pathogenic
traits are maintained, a question that not only concerns CagA(G) Cells were transfected with siRNA against hBD3 or control siRNA (Allstars). T
assessed from attached bacteria.
Data in (A), (B), and (D)–(G) showmean ± SD of three technical replicates. The blot
of three independent experiments. Statistical significance in (D)–(G) was calculate
See also Figure S5.
Cell Hstatus but, principally, also other H. pylori virulence attributes.
Intriguingly, the hBD3 gene cluster, DEFB103A, the expression
of which we found to be antagonized by CagA, exhibits single
nucleotide polymorphisms as well as extensive copy number
variations (Hollox et al., 2003; Linzmeier and Ganz, 2005).
Chinese populations maintain higher copy numbers of the b-de-
fensin genomic locus than, for example, European populations
(Hollox, 2008). A worldwide study of b-defensin copy number
variations in 67 human populations reported frequent occur-
rence of a high hBD3-expressing gene variant in East Asia (Hard-
wick et al., 2011). This correlates with the observation that most
Asian H. pylori isolates express a highly pathogenic CagA
protein, harboring the EPIYA-D tyrosine phosphorylation motif,
which exhibits high affinity for binding to SHP-2 (Higashi et al.,
2002a). The co-occurrence of CagA EPIYA-D and increased
DEFB103A copy numbers in Asia argues for an escalated inter-
play between pathogen and host in that geographic region.
In addition to host factors, the bacterial genetic composition
could necessitate the function of CagA as an immunosuppres-
sive factor. Approximately one-third of the genes in H. pylori
isolates are variably expressed (Gressmann et al., 2005). Thus,
whether the immunoregulatory CagA function is required for
successful colonization likely depends on the genetic context
of both bacterium and host. Moreover,H. pylori exerts additional
CagA-independent immunosuppressive functions, mediated, for
example, by epithelial cells via the uptake and glucosylation of
cholesterol (Wunder et al., 2006) and by the manipulation of
T cell-mediated immunity by GGT and VacA (Boncristiano
et al., 2003; Gebert et al., 2003; Torres et al., 2007). Such
complementary mechanisms may safeguard the existence of
CagA-negative strains.
Finally, the interplay between CagA and hBD3 has direct
implications for host pathology as both EGFR and hBD3 function
in wound healing processes (Tarnawski and Jones, 1998). Inac-
tivation of the EGF receptor tyrosine kinase duringH. pylori infec-
tion could, therefore, provide a rationale for the generation of
ulcerative lesions, which are a hallmark of CagA expressing
H. pylori strains (Argent et al., 2008). Our delineation of the
CagA-dependent activation of SHP-2 during H. pylori infection
identifies SHP-2 as a promising target for future antimicrobial
therapy, and beyond that, the treatment of ulcers.EXPERIMENTAL PROCEDURES
Cell Lines, Tissue, and Bacterial Strains
The human gastric adenocarcinoma cell line AGS (ATCC) was grown in RPMI
1640medium containing 4mMglutamine (Invitrogen) and 10% fetal calf serum
(GIBCO). Cells were incubated in a humidified atmospherewith 5%CO2. Type I
H. pylori wild-type strains P1, P12, G27, and 251 are clinical isolates that have
been described previously (Censini et al., 1996; Covacci et al., 1993; Philpott
et al., 2002; Schmitt and Haas, 1994). Construction of the isogenic knockout
mutants P1DcagA and P1DvirB11 are described elsewhere (Backert et al.,
2010). Bacterial cultivation is described in the Supplemental Experimental
Procedures.hree days after transfection, cells were infected with P1 (MOI 100). CFU was
in (A), bar graphs in (B) and (D)–(G), and images in (C) and (E) are representative
d with t test analysis (*** indicates p value < 0.0007; * indicates p value < 0.05).
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H. pylori Evades hBD3 Bactericidal ActivityFor the ex vivo tissue model, Fallopian tubes were provided by Department
of Gynecology, Charite´ University Hospital, Campus Virchow Clinic, Berlin.
The scientific use of samples for experimental purposes was approved by
the Ethics Commission of the Charite´, Berlin (EA1/002/07). Tubal fragments
were remnants from standard surgical procedures.
Antimicrobial Activity Assay
Bacteria (1 3 105) were incubated for 2 hr at 37C with or without indicated
concentrations of recombinant hBD3 and hBD2. Subsequently, bacteria
were diluted (101, 102, 103, and 104) in PBS containing 50 mM, 80 mM,
or 137 mM NaCl to a final volume of 1 ml. Bacterial suspensions (20 ml) were
plated on agar plates and incubated for 3 days at 37C. Numbers of surviving
bacteria were expressed in percent relative to untreated bacterial samples.
Full details are given in the Supplemental Experimental Procedures.
siRNA and DNA Transfection
AGS cells were transiently transfected with either DNA or siRNA using
Lipofectamine 2000 (Invitrogen) or RNAifect (Invitrogen), respectively,
following themanufacturer’s instructions. The plasmids encoding the constitu-
tive active EGFR (EGFR L858R) and wild-type EGFR (EGFRWT) (Uchida et al.,
2007) were a generous gift from Katsuyuki Kiura and Akiko Uchida. The
plasmid encoding SHP-2 (Avril et al., 2004) was kindly provided by Paul
Crocker. siRNAs used were as follows: SHP-2 (2r), AAGGUGGUUUCAUGGA
CAUCU; SHP-2 (1), GAAUAUGGCGUCAUGCGUGTT; SHP-2 (2), CCUUAA
CACGACUCGUAUAAA; SHP-2 (3), GCGUCAUGCGUGUUAGGAACG; and
hBD3 (8), AGCAGCTATGAGGATCCATTA. Luciferase was used as a control
(AACUUACGCUGAGUACUUCGA).
Construction of Stable SHP-2 Knockdown Cell Lines
shRNAs for SHP-2 constructs were stably transduced into AGS cells with
a lentiviral-based expression system (Wiznerowicz and Trono, 2003). shRNAs
were designed with the BLOCK-iTTM RNAi Designer (Invitrogen) and cloned
into the vector pLVTHM. 293T cells were transfected with calcium phosphate
together with the packaging vectors psPAX2 und pMD2G. Viruses harvested
from the supernatant were used for infection of HeLa cells in the presence
of polybrene (5 mg/ml). GFP-positive cells were selected after 7 days of
infection and sorted into 96-well plates with flow cytometry. Target sequences
were as follows: SHP2-1, GCCTCATATGTTGAATCATCC, and SHP2-4,
GGGATCAACTTTCACACATAG.
Statistical Analysis
Statistical analysis was performed by Student’s t test. At least three indepen-
dent biological replicates were used for p value calculation. The level of signif-
icance was determined at p < 0.01 or p < 0.001.
Full details for EGF and HB-EGF stimulation and inhibitor treatment, WST-1
viability assay, ATP luciferase assay, immunofluorescence, electron micros-
copy, quantification, 3D reconstruction, and immunoblotting and analysis
are given in the Supplemental Experimental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and five figures and can be found with this article online at doi:10.1016/
j.chom.2012.04.013.
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